|
WO2021066559A1
|
|
N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
|
|
WO2021040356A1
|
|
C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition
|
|
WO2019152546A2
|
|
Salt forms of organic compound
|
|
CA3067135A1
|
|
Modulators of alpha-synuclein
|
|
WO2017039318A1
|
|
Benzimidazole derivatives for dna methylation inhibitors
|
|
WO2016195353A1
|
|
A use of 1'-cyano-cytarabine for cancer treatment
|
|
WO2016186453A1
|
|
Quinoline derivatives as bromodomain inhibitors
|
|
WO2016171470A1
|
|
Bromodomain-inhibiting compounds and methods to prevent or treat a cancer
|
|
WO2016140501A1
|
|
Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors
|
|
EP3129378A1
|
|
Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer
|
|
EP3068406A1
|
|
Mutual prodrug comprising short chain fatty acids and zebularine or 1'-cyano-cytarabine for cancer treatment
|
|
WO2014042433A2
|
|
Compounds and compositions for modulating adenosine a3 receptor activity
|
|
WO2014035140A2
|
|
Compounds and compositions for modulating histone methyltransferase activity
|
|
US2015157611A1
|
|
Compounds as inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
|
|
WO2011156355A1
|
|
Production method of phenyl guanidine salts and their intermediates
|
